• Income Statement
• Balance Sheet
• Cash Flow
• Ratios
• Market Data
• Valuation

	Advanced Biomed Inc. (ADVB)
	Q4-CY2026	Q3-CY2026	Q2-CY2026	Q1-CY2026	Q4-CY2025	Q3-CY2025	Q2-CY2025	Q1-CY2025	Q4-CY2024	Q3-CY2024	Q2-CY2024	Q1-CY2024	Q4-CY2023	Q3-CY2023	Q2-CY2023	Q1-CY2023	Q4-CY2022	Q3-CY2022	Q2-CY2022	Q1-CY2022	Q4-CY2021	Q3-CY2021	Q2-CY2021	Q1-CY2021	Q4-CY2020	Q3-CY2020	Q2-CY2020	Q1-CY2020	Q4-CY2019	Q3-CY2019	Q2-CY2019	Q1-CY2019	Q4-CY2018	Q3-CY2018	Q2-CY2018	Q1-CY2018	Q4-CY2017	Q3-CY2017	Q2-CY2017	Q1-CY2017	Q4-CY2016	Q3-CY2016	Q2-CY2016	Q1-CY2016	Q4-CY2015	Q3-CY2015	Q2-CY2015	Q1-CY2015	Q4-CY2014
Balance Sheet Date			2026-Jun-30	2026-Mar-31	2025-Dec-31	2025-Sep-30	2025-Jun-30	2025-Mar-31	2024-Dec-31
Fiscal Period			Q4-FY2026	Q3-FY2026	Q2-FY2026	Q1-FY2026	Q4-FY2025	Q3-FY2025	Q2-FY2025
Total Revenue
QoQ%
YoY%
Cost Of Revenue
Gross Profit
Gross Margin
Operating Expenses			5,049,826$	519,836$	396,642$	523,914$	11,321$	567,507$	280,064$	520,027$	704,613$	745,412$	651,302$
Operating Income
Operating Margin
Interest Income			0$	0$	9,206$	448$	9,512$	(24$)	15,377$	10$	33,411$	104$	19,966$
Interest Expenses			16,108$	112$
Income Before Tax			(12,517,038$)	(488,942$)	7,002,178$	(386,901$)	675,636$	(1,197,499$)	(579,494$)	(265,580$)	(809,386$)	(1,056,231$)	(145,345$)
Tax Expenses
Net Income			694,999$	(488,942$)	6,857,921$	(386,901$)	(701,611$)	(1,383,874$)	(907,904$)	(265,580$)	(809,386$)	(1,056,231$)	(145,345$)
Profit Margin
TTM
Earnings to Minority
Earnings to Common Shareholders			694,999$	(488,942$)	6,857,921$	(386,901$)	(701,611$)	(1,383,874$)	(907,904$)	(265,580$)	(809,386$)	(1,056,231$)	(145,345$)
QoQ%			242.14%	(107.13%)	1,872.53%	44.86%	49.30%	(52.43%)	(241.86%)	67.19%	23.37%	(626.71%)
YoY%			199.06%	64.67%	855.36%	(45.68%)	13.32%	(31.02%)	(524.65%)
Earnings Per Share, Basic			(0.02$)	(0.38$)	0.32$	(0.02$)	0.02$	(1.35$)	(0.05$)	(0.01$)		(0.05$)	(0.01$)
Earnings Per Share, Diluted			(0.02$)	(0.38$)	0.32$	(0.02$)	0.02$	(1.35$)	(0.05$)	(0.01$)		(0.05$)	(0.01$)
Unlevered FCF Per Share, Basic			0.01$	(0.19$)	(0.02$)	(0.03$)	0.04$	(3.33$)		0.00$		(0.05$)
Unlevered FCF Per Share, Diluted			0.01$	(0.19$)	(0.02$)	(0.03$)	0.04$	(3.33$)		0.00$		(0.05$)
Average Shares, Basic			-39,554,015	1,284,923	21,640,000	21,640,000	-36,918,815	1,023,955	20,000,000	20,000,000		20,000,000	20,000,000
Average Shares, Diluted			-39,554,015	1,284,923	21,640,000	21,640,000	-36,918,815	1,023,955	20,000,000	20,000,000		20,000,000	20,000,000
EBIT			(12,500,930$)	(488,830$)	7,002,178$	(386,901$)	675,636$	(1,197,499$)	(579,494$)	(265,580$)	(809,386$)	(1,056,231$)	(145,345$)
EBITDA			(12,500,930$)	(479,504$)	6,989,321$	(338,909$)	951,501$	(1,174,992$)	(636,254$)	(163,362$)	(655,475$)	(973,215$)	(145,345$)

Copy Table ✓